who is not a good candidate for glp 1 GLP-1 medications are changing the conversation around weight and metabolic health, but they're everyone. Swipe to find out if you might be candidate, what the science says, and what Not everyone is a good

This central GIPR activity is one reason tirzepatide reduces cravings and alters food preferences in ways patients frequently describe as different from their experience with GLP-1-only agents

Side Effects & Safety Transient headache -- the most commonly reported side effect Mild nausea -- usually resolves within 30 minutes Temporary dizziness/vertigo -- reported at higher doses Injection site redness -- standard for SC peptides No lethal dose identified in animal studies No dependency or withdrawal documented No respiratory depression -- unlike pharmaceutical sleep aids DSIP appears on the FDA's list of bulk drug substances that raise potential safety concerns

Tau PET is the more informative progression marker because it maps where pathology sits and tracks cognitive change more closely than amyloid load does

PMID: 25738458